

Overzicht publicaties OncoLifeS

2023

1. Bolte LA, Lee KA, Björk JR, Leeming ER, Campmans-Kuijpers MJE, de Haan JJ, Vila AV, Maltez-Thomas A, Segata N, Board R, Harries M, Lorigan P, de Vries EGE, Nathan P, Fehrmann R, Bataille V, Spector TD, Hospers GAP, Weersma RK. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. *JAMA Oncol.* 2023 May 1;9(5):705-709. doi: [10.1001/jamaoncol.2022.7753](https://doi.org/10.1001/jamaoncol.2022.7753). PMID: 36795408; PMCID: PMC9936383.
2. Cuzzocrea A, De Bock GH, Maas WJ, Soufargi S. F-TBDA: A Frequency-Based Temporal Big Data Analytics Technique for Mining and Analyzing Quality-Of-Life Indicators of Cancer Patients. *IEEE International Conference On Big Data (BigData)*. 2023 dec 15; doi: [10.1109/bigdata59044.2023.10386767](https://doi.org/10.1109/bigdata59044.2023.10386767)
3. Dewansingh P, Bras L, Ter Beek L, Krijnen WP, Roodenburg JLN, van der Schans CP, Halmos GB, Jager-Wittenaar H. Malnutrition risk and frailty in head and neck cancer patients: coexistent but distinct conditions. *Eur Arch Otorhinolaryngol.* 2023 Apr;280(4):1893-1902. doi: [10.1007/s00405-022-07728-6](https://doi.org/10.1007/s00405-022-07728-6). Epub 2022 Dec 9. PMID: 36484854; PMCID: PMC9988738.
4. Griessinger E, Pereira-Martins D, Nebout M, Bosc C, Saland E, Boet E, Sahal A, Chiche J, Debayle D, Fleuriot L, Pruis M, De Mas V, Vergez F, Récher C, Huls G, Sarry JE, Schuringa JJ, Peyron JF. Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold. *Cancer Res.* 2023 Aug 1;83(15):2461-2470. doi: [10.1158/0008-5472.CAN-23-1006](https://doi.org/10.1158/0008-5472.CAN-23-1006). PMID: 37272750; PMCID: PMC10391327.
5. Lanjouw L, Mourits MJE, Bart J, Ter Elst A, Berger LPV, van der Hout AH, Alam N, de Bock GH. BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients. *Int J Gynecol Cancer.* 2023 Aug 7;33(8):1260-1269. doi: [10.1136/ijgc-2023-004307](https://doi.org/10.1136/ijgc-2023-004307). PMID: 37137525; PMCID: PMC10423510.
6. Lima K, Carvalho MFL, Pereira-Martins DA, Nogueira FL, de Miranda LBL, Nascimento MCD, Cavaglieri RC, Schuringa JJ, Machado-Neto JA, Rego EM. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia. *Int J Mol Sci.* 2023 Nov 29;24(23):16899. doi: [10.3390/ijms242316899](https://doi.org/10.3390/ijms242316899). PMID: 38069220; PMCID: PMC10706459.
7. Stuursma A, van der Vegt B, Jansen L, Berger LPV, Mourits MJE, de Bock GH. The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant. *Cancers (Basel).* 2023 Mar 31;15(7):2095. doi: [10.3390/cancers15072095](https://doi.org/10.3390/cancers15072095). PMID: 37046756; PMCID: PMC10093102.

8. Suazo-Zepeda E, Vinke PC, Heuvelmans MA, Sidorenkov G, Hiltermann TJN, de Bock GH. Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age. *Lung Cancer*. 2023 Feb;176:89-97. doi: [10.1016/j.lungcan.2022.12.017](https://doi.org/10.1016/j.lungcan.2022.12.017). Epub 2022 Dec 30. PMID: 36628904.
9. van der Kamp MF, Hiddingh E, de Vries J, van Dijk BAC, Schuurin E, Slagter-Menkema L, van der Vegt B, Halmos GB. Association of Tumor Microenvironment with Biological and Chronological Age in Head and Neck Cancer. *Cancers (Basel)*. 2023 Jul 28;15(15):3834. doi: [10.3390/cancers15153834](https://doi.org/10.3390/cancers15153834). PMID: 37568649; PMCID: [PMC10417631](https://pubmed.ncbi.nlm.nih.gov/PMC10417631/).
10. Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. *EClinicalMedicine*. 2023 Apr 13;59:101955. doi: [10.1016/j.eclinm.2023.101955](https://doi.org/10.1016/j.eclinm.2023.101955). PMID: 37125403; PMCID: [PMC10139887](https://pubmed.ncbi.nlm.nih.gov/PMC10139887/).
11. Veltmaat N, Zhong Y, de Jesus FM, Tan GW, Bult JAA, Terpstra MM, Mutsaers PGNJ, Stevens WBC, Mous R, Vermaat JSP, Chamuleau MED, Noordzij W, Verschuuren EAM, Kok K, Kluiver JL, Diepstra A, Plattel WJ, van den Berg A, Nijland M. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA. *J Hematol Oncol*. 2023 Sep 14;16(1):104. doi: [10.1186/s13045-023-01500-x](https://doi.org/10.1186/s13045-023-01500-x). PMID: [37705050](https://pubmed.ncbi.nlm.nih.gov/37705050/); PMCID: [PMC10500745](https://pubmed.ncbi.nlm.nih.gov/PMC10500745/).
12. Visconti A, Rossi N, Deriš H, Lee KA, Hanić M, Trbojević-Akmačić I, Thomas AM, Bolte LA, Björk JR, Hooiveld-Noeken JS, Board R, Harland M, Newton-Bishop J, Harries M, Sacco JJ, Lorigan P, Shaw HM, de Vries EGE, Fehrmann RSN, Weersma RK, Spector TD, Nathan P, Hospers GAP, Sasieni P, Bataille V, Lauc G, Falchi M. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma. *BMC Cancer*. 2023 Feb 18;23(1):166. doi: [10.1186/s12885-023-10511-3](https://doi.org/10.1186/s12885-023-10511-3). PMID: 36805683; PMCID: [PMC9938582](https://pubmed.ncbi.nlm.nih.gov/PMC9938582/).
13. Weinhäuser I, Pereira-Martins DA, Almeida LY, Hilberink JR, Silveira DRA, Quek L, Ortiz C, Araujo CL, Bianco TM, Lucena-Araujo A, Mota JM, Hogeling SM, Sternadt D, Visser N, Diepstra A, Ammatuna E, Huls G, Rego EM, Schuringa JJ. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism. *Sci Adv*. 2023 Apr 14;9(15):eadf8522. doi: [10.1126/sciadv.adf8522](https://doi.org/10.1126/sciadv.adf8522). Epub 2023 Apr 14. PMID: 37058562.
14. Zwart AT, Cavalheiro VJ, Lamers MJ, Dierckx RAJO, de Bock GH, Halmos GB, van der Hoorn A. The validation of low-dose CT scans from the [18F]-FDG PET-CT scan to

assess skeletal muscle mass in comparison with diagnostic neck CT scans. *Eur J Nucl Med Mol Imaging*. 2023 May;50(6):1735-1742. doi: [10.1007/s00259-023-06117-3](https://doi.org/10.1007/s00259-023-06117-3). Epub 2023 Feb 13. PMID: 36781423; PMCID: [PMC10119057](https://pubmed.ncbi.nlm.nih.gov/PMC10119057/).

15. Zwart AT, Kok LMC, de Vries J, van Kester MS, Dierckx RAJO, de Bock GH, van der Hoorn A, Halmos GB. Radiologically Defined Sarcopenia as a Biomarker for Frailty and Malnutrition in Head and Neck Skin Cancer Patients. *J Clin Med*. 2023 May 13;12(10):3445. doi: [10.3390/jcm12103445](https://doi.org/10.3390/jcm12103445). PMID: 37240550; PMCID: [PMC10218972](https://pubmed.ncbi.nlm.nih.gov/PMC10218972/).

2022

16. Schoonbeek RC, Festen S, Rashid R, van Dijk BAC, Halmos GB, van der Velden LA. Impact of Delay on Hospitalization in Older Patients With Head and Neck Cancer: A Multicenter Study. *Otolaryngol Head Neck Surg*. 2022 Oct;167(4):678-687. doi: [10.1177/01945998211072828](https://doi.org/10.1177/01945998211072828). Epub 2022 Jan 19. DOI: [10.1177/01945998211072828](https://doi.org/10.1177/01945998211072828)
17. Koopman B, Groen HJM, Schuurin E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. *Clin Lung Cancer*. 2022 Mar;23(2):e104-e115. DOI: [10.1016/j.clcc.2021.06.011](https://doi.org/10.1016/j.clcc.2021.06.011)
18. Erdem A, Marin S, Pereira-Martins DA, Cortés R, Cunningham A, Pruis MG, de Boer B, van den Heuvel FAJ, Geugien M, Wierenga ATJ, Brouwers-Vos AZ, Rego EM, Huls G, Cascante M, Schuringa JJ. The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia. *Nat Commun*. 2022 Mar 1;13(1):1105. DOI: [10.1038/s41467-022-28737-3](https://doi.org/10.1038/s41467-022-28737-3)
19. Erdem A, Marin S, Pereira-Martins DA, Geugien M, Cunningham A, Pruis MG, Weinhäuser I, Gerding A, Bakker BM, Wierenga ATJ, Rego EM, Huls G, Cascante M, Schuringa JJ. Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability. *Nat Commun*. 2022 Apr 19;13(1):2013. DOI: [10.1038/s41467-022-29639-0](https://doi.org/10.1038/s41467-022-29639-0)
20. Houtsma R, van der Meer NK, Meijer K, Morsink LM, Hogeling SM, Woolthuis CM, Ammatuna E, Nijk MT, de Boer B, Huls G, Mulder AB, Schuringa JJ. CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. *Blood Adv*. 2022 Apr 12;6(7):2129-2143. DOI: [10.1182/bloodadvances.2021005018](https://doi.org/10.1182/bloodadvances.2021005018)
21. Gerritsen M, Hilgendorf S, Yi G, Wierenga ATJ, Schuringa JJ, Martens JHA, Vellenga E. Presence of mutant p53 increases stem cell frequency and is associated with

reduced binding to classic TP53 binding sites in cell lines and primary AMLs. *Exp Hematol.* 2022 Jun;110:39-46. DOI: [10.1016/j.exphem.2022.03.007](https://doi.org/10.1016/j.exphem.2022.03.007)

22. Schoonbeek RC, de Vries J, Bras L, Sidorenkov G, Plaat BEC, Witjes MJH, van der Laan BFAM, van den Hoek JGM, van Dijk BAC, Langendijk JA, Halmos GB. The effect of treatment delay on quality of life and overall survival in head and neck cancer patients. *Eur J Cancer Care (Engl).* 2022 Jul;31(4):e13589. doi: 10.1111/ecc.13589. Epub 2022 Apr 19. DOI: [10.1111/ecc.13589](https://doi.org/10.1111/ecc.13589)
23. Li W, Kok K, Tan GW, Meng P, Mastik M, Rifaela N, Scherpen F, Hiltermann TJN, Groen HJM, Wekken AJV, van den Berg A. The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare. *Cancers (Basel).* 2022 Jul 19;14(14):3511. DOI: [10.3390/cancers14143511](https://doi.org/10.3390/cancers14143511)
24. de Vries J, Poelman A, Sidorenkov G, Festen S, de Bock GH, Langendijk JA, van der Laan BFAM, Steenbakkens RJHM, Halmos GB. The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer. *Oral Oncol* 2022; 130: 105933. July 2022 DOI: [10.1016/j.oraloncology.2022.105933](https://doi.org/10.1016/j.oraloncology.2022.105933)
25. Zwart AT, Pörtzgen W, van Rijn-Dekker I, Sidorenkov GA, Dierckx RAJO, Steenbakkens RJHM, Wegner I, van der Hoorn A, de Bock GH, Halmos GB. Sex-Specific Cut-Off Values for Low Skeletal Muscle Mass to Identify Patients at Risk for Treatment-Related Adverse Events in Head and Neck Cancer. *J Clin Med.* 2022 Aug 9;11(16):4650. DOI: [10.3390/jcm11164650](https://doi.org/10.3390/jcm11164650)
26. Schoonbeek RC, Festen S, van der Laan BFAM, Plaat BEC, Langendijk JA, van Dijk BAC, Halmos GB. The effect of delayed primary treatment initiation on adverse events and recurrence in older head and neck cancer patients. *Radiother Oncol.* 2022 Aug;173:154-162. Epub 2022 Jun 6. DOI: [10.1016/j.radonc.2022.06.001](https://doi.org/10.1016/j.radonc.2022.06.001)
27. Vilaplana-Lopera N, Cuminetti V, Almaghrabi R, Papatzikas G, Rout AK, Jeeves M, González E, Alyahyawi Y, Cunningham A, Erdem A, Schnütgen F, Raghavan M, Potluri S, Cazier JB, Schuringa JJ, Reed MAC, Arranz L, Günther UL, Garcia P. Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells. *Elife.* 2022 Sep 2;11:e75908. DOI: [10.7554/eLife.75908](https://doi.org/10.7554/eLife.75908)
28. Lima K, Pereira-Martins DA, de Miranda LBL, Coelho-Silva JL, Leandro GDS, Weinhäuser I, Cavaglieri RC, Leal AM, da Silva WF, Lange APAL, Velloso EDRP, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Rego EM, Machado-Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. *Blood Cancer J.* 2022 Nov 9;12(11):151. DOI: [10.1038/s41408-022-00747-w](https://doi.org/10.1038/s41408-022-00747-w)

29. Cunningham A, Erdem A, Alshamleh I, Geugien M, Pruis M, Pereira-Martins DA, van den Heuvel FAJ, Wierenga ATJ, Ten Berge H, Dennebos R, van den Boom V, Hogeling SM, Weinhäuser I, Knops R, de Blaauw P, Heiner-Fokkema MR, Woolthuis C, Günther UL, Rego EM, Martens JHA, Jansen JH, Schwalbe H, Huls G, Schuringa JJ. Dietary methionine starvation impairs acute myeloid leukemia progression. *Blood*. 2022 Nov 10;140(19):2037-2052. DOI: [10.1182/blood.2022017575](https://doi.org/10.1182/blood.2022017575)
30. Ortiz Rojas CA, Costa-Neto A, Pereira-Martins DA, Le DM, Sternadt D, Weinhäuser I, Huls G, Schuringa JJ, Magalhães Rego E. High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia. *Cancers (Basel)*. 2022 Dec 31;15(1):296. DOI: [10.3390/cancers15010296](https://doi.org/10.3390/cancers15010296)

2021

31. Bras L, de Vries J, Festen S, Steenbakkens RJHM, Langendijk JA, Witjes MJH, van der Laan BFAM, de Bock GH, Halmos GB. Frailty and restrictions in geriatric domains are associated with surgical complications but not with radiation-induced acute toxicity in head and neck cancer patients: A prospective study. *Oral Oncol* 2021 Jul;118:105329. doi: [10.1016/j.oraloncology.2021.105329](https://doi.org/10.1016/j.oraloncology.2021.105329)
32. Schoonbeek RC, de Vries J, Bras L, Plaat BEC, van Dijk BAC, Halmos GB. Determinants of delay in the head and neck oncology care pathway: The next step in value-based health care. *Eur J Cancer Care (Engl)*. 2021 Jul;30(4):e13419. doi: [10.1111/ecc.13419](https://doi.org/10.1111/ecc.13419).
33. van der Zanden V, van Soolingen NJ, Viddeleer AR, Trum JW, Amant F, Mourits MJE, Portielje JEA, van den Bos F, de Kroon CD, Kagie MJ, Oei SA, Baalbergen A, van Haaften-de Jong AMLD, Houtsma D, van Munster BC, Souwer ETD. Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. *Gynecol Oncol* 2021 Aug;162(2):360-367. doi: [10.1016/j.ygyno.2021.05.039](https://doi.org/10.1016/j.ygyno.2021.05.039).
34. Koopman B, Groen HJM, Schuurung E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. *Clin Lung Cancer* 2021 Jul 3;S1525-7304(21)00178-9. doi: [10.1016/j.clcc.2021.06.011](https://doi.org/10.1016/j.clcc.2021.06.011).
35. van der Zanden V, van Soolingen NJ, Viddeleer AR, Trum JW, Amant F, Mourits MJE, Portielje JEA, Baalbergen A, Souwer ETD van Munster BC. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. *Eur J Surg Oncol* 2021 Oct 22;S0748-7983(21)00766-6. doi: [10.1016/j.ejso.2021.10.015](https://doi.org/10.1016/j.ejso.2021.10.015).

36. Zwart AT, Becker JN, Lamers MJ, Dierckx RAJO, de Bock GH, Halmos GB, van der Hoorn A. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. *Eur Radiol.* 2021 Jun;31(6):4053-4062.
37. de Vries J, Bras L, Sidorenkov G, Festen S, Steenbakkers RJ, Langendijk JA, Witjes MJH, van der Laan BFAM, de Bock GH, Halmos GB. Association of Deficits Identified by Geriatric Assessment With Deterioration of Health-Related Quality of Life in Patients Treated for Head and Neck Cancer. *JAMA Otolaryngol Head Neck Surg* 2021 Dec 1;147(12):1089-1099. doi: 10.1001/jamaoto.2021.2837.
38. de Almeida LY, Pereira-Martins DA, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, De Abreu NF, Mendonza SES, de Deus Wagatsuma VM, Do Nascimento MC, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. [The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells.](#) *Front Oncol.* 2021 Sep 28;11:686445. doi: 10.3389/fonc.2021.686445. eCollection 2021.PMID: 34650910 Free PMC article.
39. Houtsma R, Hogeling SM, Schuringa JJ. [CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones.](#) *STAR Protoc.* 2021 Sep 27;2(4):100864. doi: 10.1016/j.xpro.2021.100864. eCollection 2021 Dec 17.PMID: 34622222 Free PMC article.
40. Houtsma R, van der Meer NK, Meijer K, Morsink L, Hogeling SM, Woolthuis C, Ammatuna E, Nijk M, de Boer B, Huls G, Mulder AB, Schuringa JJ. [CombiFlow: Combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.](#) *Blood Adv.* 2021 Sep 20:bloodadvances.2021005018. doi: 10.1182/bloodadvances.2021005018. Online ahead of print.PMID: 34543390
41. Maat H, Atsma TJ, Hogeling SM, Rodríguez López A, Jaques J, Olthuis M, de Vries MP, Gravesteijn C, Brouwers-Vos AZ, van der Meer N, Datema S, Salzbrunn J, Huls G, Baas R, Martens JHA, van den Boom V, Schuringa JJ. [The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia.](#) *iScience.* 2021 Apr 16;24(5):102435. doi: 10.1016/j.isci.2021.102435. eCollection 2021 May 21.PMID: 34113809
42. Wei J, Meng P, Terpstra MM, van Rijk A, Tamminga M, Scherpen F, Ter Elst A, Alimohamed MZ, Johansson LF, Stigt J, Gijtenbeek RPG, van Putten J, Hiltermann TJN, Groen HJM, Kok K, van der Wekken AJ, van den Berg A. Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC. *Target Oncol.* 2021 Mar;16(2):215-226. doi: 10.1007/s11523-021-00798-2. Epub 2021 Feb 19. PMID: 33606136

2020

43. Zwart AT, Becker JN, Lamers MJ, Dierckx RAJO, de Bock GH, Halmos GB, van der Hoorn A. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. *Eur Radiol*. 2020 Nov 21. doi: 10.1007/s00330-020-07440-1.
44. Vries de J, Bras L, Sidorenkov G, Festen S, Steenbakkens RJHM, Langendijk JA, Witjes MJH, van der Laan BFAM, de Bock GH, Halmos GB. Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer. *Oral Oncol*. 2020 Dec;111:105020. doi: 10.1016/j.oraloncology.2020.105020.
45. Bras L, Driessen DAJJ, de Vries J, Festen S, van der Laan BFAM, van Leeuwen BL, de Bock GH, Halmos GB. Patients with head and neck cancer: Are they frailer than patients with other solid malignancies? *Eur J Cancer Care (Engl)*. 2020 Jan;29(1):e13170. doi: 10.1111/ecc.13170.
46. de Vries J, Heirman AN, Bras L, Plaat BEC, Rácz E, van Kester MS, Festen S, de Bock GH, van der Laan BFAM, Halmos GB. Geriatric assessment of patients treated for cutaneous head and neck malignancies in a tertiary referral center: Predictors of postoperative complications. *Eur J Surg Oncol*. 2020 Jan;46(1):123-130. doi: 10.1016/j.ejso.2019.08.008.
47. Bras L, Driessen DAJJ, de Vries J, Festen S, van der Laan BFAM, van Leeuwen BL, et al. Patients with head and neck cancer: Are they frailer than patients with other solid malignancies? *Eur J Cancer Care (Engl)*. 2020 Jan;29(1):e13170. doi: 10.1111/ecc.13170. Epub 2019 Sep 30.
48. de Vries J, Heirman AN, Bras L, Plaat BEC, Rácz E, van Kester MS, Festen S, de Bock GH, van der Laan BFAM, Halmos GB. Geriatric assessment of patients treated for cutaneous head and neck malignancies in a tertiary referral center: Predictors of postoperative complications. *Eur J Surg Oncol*. 2020 Jan;46(1):123-130. doi: 10.1016/j.ejso.2019.08.008. Epub 2019 Aug 10.
49. Gerda de Vries, Ximena Rosas-Plaza, Gert Jan Meersma, Vincent C. Leeuwenburgh, Klaas Kok, Albert J. H. Suurmeijer, Marcel A. T. M. van Vugt, Jourik A. Gietema, Steven de Jong. Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies. *Scientific Reports* volume 10, Article number: 18938 (2020)
50. Pei Meng, Anna A. Rybczynska, Jiacong Wei, Miente Martijn Terpstra, Wim Timens, Ed Schuurings, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg, Klaas Kok. Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients. doi: <https://doi.org/10.1101/2021.01.26.21250013>

2014-2019

51. Berger G, Gerritsen M, Yi G, Koorenhof-Scheele TN, Kroeze LI, Stevens-Kroef M, Yoshida K, Shiraishi Y, van den Berg E, Schepers H, Huls G, Mulder AB, Ogawa S, Martens JHA, Jansen JH, Vellenga E. Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. *Blood Adv.* 2019; 3: 3111-22.
52. Berger G, Kroeze LI, Koorenhof-Scheele TN, de Graaf AO, Yoshida K, Ueno H, Shiraishi Y, Miyano S, van den Berg E, Schepers H, van der Reijden BA, Ogawa S, Vellenga E, Jansen JH. Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. *Blood* 2018; 131: 1846-57.
53. Bras L, Driessen DAJJ, de Vries J, Festen S, van der Laan BFAM, van Leeuwen BL, et al. Patients with head and neck cancer: Are they frailer than patients with other solid malignancies? *Eur J Cancer Care (Engl)*. 2019 (Epub ahead of print).
54. de Arruda FN, Oonk MHM, Mourits MJE, de Graeff P, Jalving M, de Bock GH. Determinants of health-related quality of life in elderly ovarian cancer patients: the role of frailty and dependence. *Gynecol Oncol.* 2019; 153: 610–5.
55. de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, Brouwers-Vos AZ, Hogeling SM, Woolthuis CM, Nijk MT, Diepstra A, Wandinger S, Versele M, Attar RM, Cockerill PN, Huls G, Vellenga E, Mulder AB, Bonifer C, Schuringa JJ. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. *Cancer Cell* 2018; 34: 674-689.
56. de Vries J, Heirman AN, Bras L, Plaat BEC, Rácz E, van Kester MS, Festen S, de Bock GH, van der Laan BFAM, Halmos GB. Geriatric assessment of patients treated for cutaneous head and neck malignancies in a tertiary referral center: Predictors of postoperative complications. *Eur J Surg Oncol.* [Epub ahead of print]
57. Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffey PJ, Schuringa JJ, Vellenga E. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. *Cell Death Dis.* 2017; 8: e2927.
58. Folkerts H, Wierenga AT, van den Heuvel FA, Woldhuis RR, Kluit DS, Jaques J, Schuringa JJ, Vellenga E. Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis. *Cell Death Dis* 2019; 10: 421.
59. Gerritsen M, Yi G, Tijchon E, Kuster J, Schuringa JJ, Martens JHA, Vellenga E. RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs. *Blood Adv* 2019; 3: 320-32.
60. In 't Hout FEM, Gerritsen M, Bullinger L, van der Reijden BA, Huls G, Vellenga E, Jansen JH. Transcription factor 4 (TCF4) expression predicts clinical outcome in

RUNX1 mutated and translocated acute myeloid leukemia. *Haematologica*. 2019 (Epub ahead of print).

61. Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Ter Huurne M, Wierenga ATJ, Janssen-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. *Cell Rep* 2016; 17: 2087-100.
62. Mattes K, Gerritsen M, Folkerts H, Geugien M, van den Heuvel FA, Flohr Svendsen A, Yi G, Martens JHA, Vellenga E. CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness-genes and can be targeted by the BCL2 inhibitor Venetoclax. *Haematologica* (Epub ahead of print).
63. Mourits MJ, de Bock GH. Before it catches the eye.... *Ann Transl Med*. 2019; 7. doi: 10.21037/atm.2019.11.150
64. Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH. The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective. *J Transl Med*. 2019; 17: 374.
65. Teixeira N, Mourits MJ, Oosterwijk JC, Fakkert IE, Absalom AR, Bakker SJL, van der Meer P, de Bock GH. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. *Fam Cancer* 2019; 18: 19-27.
66. van Driel C, de Bock GH, Schroevers MJ, Mourits MJ. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. *BJOG* 2019; 126: 402-11.
67. Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA. Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes. *Cell Rep*. 2019; 26: 1059-69.
68. Zwart AT, van der Hoorn A, van Ooijen PMA, Steenbakkens RJHM, de Bock GH, Halmos GB. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. *J Cachexia Sarcopenia Muscle*. 2019 Oct;10(5):1060-1069. doi: 10.1002/jcsm.12443. Epub 2019 May 27. PMID: 31134765; PMCID: PMC6818448.